GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Physiomics PLC (LSE:PYC) » Definitions » Momentum Rank

Physiomics (LSE:PYC) Momentum Rank : 0 (As of May. 17, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Physiomics Momentum Rank?

Physiomics has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Physiomics Momentum Rank Related Terms

Thank you for viewing the detailed overview of Physiomics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Physiomics (LSE:PYC) Business Description

Traded in Other Exchanges
Address
140 Eastern Avenue, Bee House, Milton Park, Oxfordshire, GBR, OX14 4SB
Physiomics PLC is a United Kingdom-based firm providing services to pharmaceutical companies through outsourced systems and computational biology. The company is mainly engaged in the development of models to streamline the drug discovery and development process. It focuses to transform oncology drug development. The company operates in the UK, European Union Switzerland and USA.

Physiomics (LSE:PYC) Headlines

No Headlines